| Literature DB >> 26110660 |
Ágnes Sonnevend1, Akela A Ghazawi1, Rayhan Hashmey2, Wafaa Jamal3, Vincent O Rotimi3, Atef M Shibl4, Amina Al-Jardani5, Seif S Al-Abri6, Waheed U Z Tariq7, Stefan Weber8, Tibor Pál1.
Abstract
To establish the role of local transmission versus possible pathogen import due to previous foreign exposure in infections caused by carbapenem non-susceptible Enterobacteriaceae in the Arabian Peninsula, 200 independent isolates collected in 16 hospitals of Saudi Arabia, Kuwait, Oman and the United Arab Emirates were studied. All strains were multidrug resistant; 42.5% of them also qualified as extremely drug resistant. The frequency of various carbapenemases varied according to the participating countries, but in the collection, as a whole, blaNDM-1 was the most frequently encountered carbapenemase gene (46.5%) followed by blaOXA-48-like gene (32.5%). A comparatively high rate (8.9%) of multi-clonal strains carrying both blaNDM and blaOXA-48-like genes in the United Arab Emirates, representing the most resistant subgroup, was encountered. No KPC-expressing isolates were detected. Three major clones of blaNDM-1 carrying Klebsiella pneumoniae of ST152 (n = 22, Saudi Arabia), ST14 (n = 7, United Arab Emirates) and ST147 types (n = 9, Oman) were identified, the latter two clones carrying similar, but not identical HI1b incompatibility type plasmids of >170 kb. While from 78.6% of the cases with documented foreign hospitalization blaNDM positive strains were isolated, these strains formed only 25.6% of all the isolates expressing this enzyme. In fact, 56.8% of the NDM, 75.7% of OXA-48-like and 90.9% of VIM positive strains were recovered from patients without documented foreign exposure, neither in the form of travel or prior hospitalization abroad, suggesting a high rate of autochthonous infections. This, considering the extensive links of these countries to the rest of the world, predicts that trends in the local epidemiology of carbapenem resistant strains may increasingly affect the spread of these pathogens on the global scale. These results call for improved surveillance of carbapenem resistant Enterobacteriaceae in the countries of the Arabian Peninsula.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26110660 PMCID: PMC4482506 DOI: 10.1371/journal.pone.0131372
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distribution of the isolates, patients, specimen types and hospitals among the participating countries.
| All | KSA | Kuwait | Oman | UAE | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| All | 200 | 54 | 27 | 63 | 56 | ||||
|
| 145 | 46 | 17 | 41 | 41 | |||||
|
| 28 | 3 | 5 | 10 | 10 | |||||
|
| 17 | 4 | 3 | 7 | 3 | |||||
| Others | 10 | 1 | 2 | 5 | 2 | |||||
|
| Age in years (x±sd) | 53.2 ± 22.0 | 57.1 ± 12.9 | 54.7 ± 27.5 | 47.9 ±24.8 | 55.3 ± 22.6 | ||||
| Male:female ratio | 1.8 | 3.15 | 0.92 | 1.42 | 2.16 | |||||
|
| Respiratory | 29.5 | 70.4 | 0.0 | 11.1 | 25.0 | ||||
| Blood | 15.5 | 20.4 | 14.8 | 9.5 | 17.9 | |||||
| Pus | 19.0 | 1.9 | 25.9 | 39.7 | 8.9 | |||||
| Urine | 21.0 | 7.4 | 59.3 | 19.0 | 17.9 | |||||
| Screening | 11.5 | 0.0 | 0.0 | 20.6 | 17.9 | |||||
| Unknown | 3.5 | 0.0 | 0.0 | 0.0 | 12.5 | |||||
|
| A | (22) | Mubarak | (16) | Royal | (63) | Mafraq | (17) | ||
| B | (15) | Adan | (5) | Tawam | (17) | |||||
| C | (17) | Amiri | (3) | SKMC | (4) | |||||
| Ibn Sina | (3) | Zayed | (2) | |||||||
| Al Ain | (1) | |||||||||
| Quasimi | (12) | |||||||||
| Kuwait | (2) | |||||||||
| Dubai City | (1) | |||||||||
Frequencies of different resistance genes among the isolates.
| Resistance classes | Resistance gene | Entire collection (% | Local collections (% | |||
|---|---|---|---|---|---|---|
| KSA (N = 54) | Kuwait (N = 27) | Oman (N = 63) | UAE (N = 56) | |||
|
|
| 46.5 | 57.4 | 22.2 | 46.0 | 48.2 |
|
| 32.5 | 33.3 | 25.9 | 44.4 | 21.4 | |
|
| 3.5 | 1.9 | 0.0 | 1.6 | 8.9 | |
|
| 6.0 | 1.9 | 29.6 | 3.2 | 1.8 | |
| No carbapenemase gene | 11.5 | 5.6 | 22.2 | 4.8 | 19.6 | |
|
|
| 15.5 | 11.1 | 0.0 | 23.8 | 17.9 |
|
| 0.5 | 0.0 | 0.0 | 1.6 | 0.0 | |
|
| 21.5 | 57.4 | 14.8 | 11.1 | 1.8 | |
* % calculated in the entire collection
& % calculated in the respective collections of specific countries
Distribution of carbapenem resistance mechanisms in isolates recovered from various specimen.
| Species | Carbapenemase produced | % in | ||||||
|---|---|---|---|---|---|---|---|---|
| All specimens | Respiratory | Blood | Urine | Pus | Unknown | Screening | ||
| All (N = 200) | NDM | 46.5 | 54.2 | 38.7 | 42.9 | 47.4 | 14.3 | 52.2 |
| OXA | 32.5 | 33.9 | 29.0 | 31.0 | 39.5 | 14.3 | 30.4 | |
| NDM-OXA | 3.5 | 3.4 | 3.2 | 4.8 | 2.6 | 0.0 | 4.3 | |
| VIM | 6.0 | 1.7 | 12.9 | 9.5 | 7.9 | 0.0 | 0.0 | |
| none | 11.5 | 6.8 | 16.1 | 11.9 | 2.6 | 71.4 | 13.0 | |
|
| NDM | 53.8 | 53.8 | 52.4 | 48.1 | 60.0 | 25.0 | 62.5 |
| OXA | 29.7 | 36.5 | 9.5 | 37.0 | 28.0 | 25.0 | 25.0 | |
| NDM-OXA | 4.8 | 3.8 | 4.8 | 7.4 | 4.0 | 0.0 | 6.3 | |
| VIM | 4.1 | 0.0 | 14.3 | 7.4 | 4.0 | 0.0 | 0.0 | |
| none | 7.6 | 5.8 | 19.0 | 0.0 | 4.0 | 50.0 | 6.3 | |
|
| NDM | 32.1 | 66.7 | 20.0 | 42.9 | 25.0 | 0.0 | 0.0 |
| OXA | 32.1 | 16.7 | 60.0 | 14.3 | 75.0 | 0.0 | 33.3 | |
| NDM-OXA | 0.0 | - | - | - | - | - | - | |
| VIM | 3.6 | 0.0 | 0.0 | 14.3 | 0.0 | 0.0 | 0.0 | |
| none | 32.1 | 16.7 | 20 | 28.6 | 0.0 | 100.0 | 66.7 | |
|
| NDM | 11.8 | 0.0 | 0.0 | 0.0 | 28.6 | 0.0 | 0.0 |
| OXA | 47.1 | 0.0 | 75.0 | 25.0 | 42.9 | 0.0 | 100.0 | |
| NDM-OXA | 0.0 | - | - | - | - | - | - | |
| VIM | 29.4 | 100.0 | 0.0 | 25.0 | 28.6 | 0.0 | 0.0 | |
| none | 11.8 | 0.0 | 25.0 | 50.0 | 0.0 | 0.0 | 0.0 | |
Antibiotic susceptibility of the strains by country, by resistance mechanism and by species.
| ERT | IMI | MER | CAZ | TIG | COL | XDR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | R (%) | MIC50 | MIC90 | R (%) | % | |
| All | 16 | >64 | 8 | 32 | 32 | 128 | >128 | >128 | 1 | 4 | 22 | 0.19 | 0.38 | 4.1 | 42.5 |
| Country | |||||||||||||||
| KSA | 16 | 64 | 16 | 32 | 32 | 64 | >128 | >128 | 1 | 2 | 7.4 | 0.19 | 0.38 | 7.5 | 18.5 |
| Kuwait | 16 | 64 | 8 | 128 | 16 | 128 | >128 | >128 | 1 | 4 | 25.9 | 0.25 | 0.38 | 4.0 | 33.3 |
| Oman | 16 | 64 | 8 | 16 | 16 | 64 | >128 | >128 | 1 | 4 | 27.0 | 0.125 | 0.38 | 3.2 | 46.0 |
| UAE | 32 | >64 | 8 | 32 | 64 | 128 | >128 | >128 | 1 | 4 | 28.6 | 0.19 | 0.25 | 1.8 | 66.0 |
| Carbapenemase | |||||||||||||||
| NDM | 16 | >64 | 16 | 32 | 32 | >128 | >128 | >128 | 1 | 4 | 22.6 | 0.19 | 0.38 | 4.4 | 49.4 |
| OXA-48-like | 8 | 32 | 8 | 32 | 16 | 32 | 128 | >128 | 1 | 4 | 16.9 | 0.19 | 0.38 | 3.1 | 29.2 |
| NDM+OXA | >64 | >64 | 16 | 128 | 128 | >128 | >128 | >128 | 2 | 4 | 50.0 | 0.19 | 0.25 | 0.0 | 71.4 |
| VIM | 8 | 32 | 8 | 32 | 16 | 128 | 128 | >128 | 1.5 | 5 | 33.3 | 0.125 | 0.25 | 8.3 | 58.3 |
| None | 64 | >64 | 4 | 8 | 64 | 128 | >128 | >128 | 0.75 | 4 | 21.7 | 0.19 | 0.38 | 9.1 | 34.8 |
| Species | |||||||||||||||
|
| 16 | >64 | 8 | 32 | 32 | >128 | >128 | >128 | 1.5 | 4 | 26.2 | 0.19 | 0.38 | 4.8 | 46.2 |
|
| 16 | >64 | 8 | 16 | 16 | >128 | >128 | >128 | 0.38 | 1 | 0.0 | 0.19 | 0.38 | 3.6 | 21.4 |
|
| 8 | 32 | 8 | 16 | 16 | 32 | 128 | >128 | 1 | 3 | 17.6 | 0.19 | 0.25 | 0.0 | 41.2 |
ERT-ertapenem, IMI—imipenem, MER—meropenem, CAZ—ceftazidime, TIG—Tigecycline, COL—colistin, XDR—extensively drug resistant
* without Proteus and Morganella
Characteristics of the major clones encountered.
| NDM plasmid | |||||||
|---|---|---|---|---|---|---|---|
| Clones | Country |
| Hospital ( | MLST | Mass (kb) | Inc | Genes co-transferred with |
| A | KSA |
| Hospital A ( | ST152 | 110 | NT |
|
| B | UAE |
| Kuwait Hospital ( | ST14 | >170 | HI1b |
|
| C | Oman |
| Royal Hospital ( | ST147 | >170 | HI1b |
|
NT = nontypable
* in one strain the ctxM, in the other one the armA gene co-transferred with the NDM plasmid
The rate of various carbapenemases in different patient groups.
| Patient groups | Frequency of (%) | |||
|---|---|---|---|---|
| XDR | NDM | OXA | VIM | |
| All with travel data (N = 150) | 36.7 | 50.0 | 36.5 | 8.0 |
| Travelled (N = 35) | 45.7 | 62.9 | 31.4 | 2.9 |
| Not travelled (N = 115) | 33.9 | 46.1 | 38.3 | 9.6 |
| All with hospitalization data (N = 159) | 38.4 | 50.3 | 35.8 | 7.5 |
| Hospitalized (N = 115) | 42.6 | 47.0 | 39.1 | 8.7 |
| Non hospitalized (N = 44) | 27.3 | 59.1 | 27.3 | 4.5 |
Frequency of strains producing different carbapenemases and expressing the XDR phenotype among patients with different hospitalization history.
| Carbapenemase/ phenotype | % in patient groups previously hospitalized in | ||||
|---|---|---|---|---|---|
| Same hospital (N = 52) | Any other hospital (N = 43) | Other domestic hospital (N = 29) | All domestic hospitals (N = 81) | Foreign hospital (N = 14) | |
| All (N = 95) | 54.7 | 45.3 | 30.5 | 85.3 | 14.7 |
| XDR | 40.4 | 53.5 | 51.7 | 44.4 | 57.1 |
| NDM | 26.9 | 67.4 | 62.1 | 39.5 | 78.6 |
| OXA | 51.9 | 23.3 | 24.1 | 42.0 | 21.4 |
| VIM | 13.5 | 7.0 | 10.3 | 12.3 | 0.0 |
* including NDM-OXA double positive and carbapenemase negative isolates, as well.